

MONOCLONAL THERAPIES

FOR EARLY STAGE
COVID19 TREATMENT

NOW THAT YOU'VE BEEN TESTED

Early-Stage Treatment Options for COVID-19

The United States FDA has made early treatment options available under an official process called an Emergency Use Authorization. These options are used to treat COVID-19 in the mild to moderate stage of symptoms. Eligible patients receive this therapy via an infusion process followed by an observation period. Many hospitals and treatment centers are now giving monoclonal antibody therapies known as Bamlanivimab/Etesevimab and Casivimerab/Imdemivab. If you have taken a COVID-19 PCR or antigen test and had a positive result, contact your health care provider or nearest hospital or medical facility as soon as possible afterwards to see if you are eligible for either of these highly effective treatments.

For more information on New Jersey's response to the COVID-19 pandemic, please visit our website at www.covid19.nj.gov.



WHO MAY BE ELIGIBLE FOR MONOCLONAL THERAPY

Have mild to moderate symptoms of COVID-19 and are within 10 days of onset of symptoms

Test positive via a PCR or antigen test for SARS-CoV-2

Are age 12 or older and weigh at least 88 pounds

Are high risk of getting very sick or becoming hospitalized because of COVID-19

WHO SHOULD NOT TAKE MONOCLONAL THERAPY

Patients already hospitalized with COVID-19

Persons who require oxygen therapy due to COVID-19

Those who are already on oxygen for other conditions but have increased their baseline oxygen due to COVID-19